Cerebrovascular, Cognitive and Cardiac Benefits of SGLT2 Inhibitors Therapy in Patients with Atrial Fibrillation and Type 2 Diabetes Mellitus: Results from a Global Federated Health Network Analysis.
Riccardo ProiettiJose Miguel Rivera-CaravacaRaquel López-GálvezStephanie L HarrisonFrancisco MarínPaula UnderhillEduard ShantsilaGarry McDowellManlio VinciguerraRhys DaviesClarissa M GiebelDeirdre A LaneGregory Yoke Hong LipPublished in: Journal of clinical medicine (2023)
In our large 'real world' analysis of patients with concomitant AF and T2DM, SGLT2i reduced the risk of cerebrovascular events, incident dementia, heart failure and death.
Keyphrases
- network analysis
- heart failure
- left ventricular
- atrial fibrillation
- glycemic control
- healthcare
- mild cognitive impairment
- public health
- cardiovascular disease
- mental health
- cognitive impairment
- health information
- health promotion
- cardiac resynchronization therapy
- cardiovascular risk factors
- stem cells
- risk assessment
- skeletal muscle
- human health
- metabolic syndrome
- weight loss
- cell therapy
- smoking cessation
- climate change
- replacement therapy